The R&D plan, focused on diseases affecting poor nations, is expected to be ready by 2008 and may benefit Indian drug firms and contract research organisations in a big way.
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
The profit margins of multinational companies importing medicines into India have been hit with the National Pharmaceutical Pricing Authority starting strict scrutiny of price approval applications for imported products.
Indian exporters of ayurvedic drugs are finding it extremely difficult to tap this high-growth segment
According to a petition filed by Quadrant in the Delhi High Court, Travel Guru allegedly copied its software solution 'Final Quadrant SuiteCase'.
Absence of operational manual that guides examiners, heavy backlog take a toll.
Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
The central government is considering an expansion of the list of fertilisers that are eligible for subsidy.
Rs 35,000 crore investment to increase capacity by 75%.
Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
Interestingly, the allegations against Indian arm of the world's largest pharma maker also relates to its acquisition of the Indian subsidiary of Parke Davis by Pfizer in 2000.
Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
Drug banks, cancer fund now health ministry's babies.
Indian companies are unable to raise prices because 35 per cent of the drugs sold in the country come under the government's price control order.
With financial results for the quarter round the corner, small- and medium-sized, export-oriented pharmaceutical companies are expecting a 5-10 per cent decline in their bottom line for the April-June period, owing to the rupee appreciation.
Another user of the data is the clinical diabetics' consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease.
The move is in line with the NPPA's recent policy of putting a cap on prices.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances